CCCatarina Carvalho

Catarina Carvalho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Catarina Carvalho has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Could Bone Biomarkers Predict Bone Turnover after Kidney Transplantation?—A Proof-of-Concept Study

    by Juliana Magalhães, Janete Quelhas-Santos, Luciano Pereira, Ricardo Neto, Inês Castro-Ferreira, Sandra Martins, João Miguel Frazão, Catarina Carvalho

    Aim: Bone disease after kidney transplant (KT) results from multiple factors, including previous bone and mineral metabolism disturbances and effects of transplant-related medications. New biomolecules have been recently associated with the development and progression of the chronic kidney disease–associated bone and mineral disorder (CKD-MBD). These include sclerostin and the soluble receptor activator of nuclear factor-kB ligand (sRANKL). Methods: To better understand the role of biomarkers in post-transplant bone disease, this study was designed to prospectively evaluate and correlate results from the histomorphometric analysis of bone biopsies after KT with emerging serum biomarkers of the CKD-MBD: sclerostin, Dickkopf-related protein 1 (Dkk-1), sRANKL and osteo-protegerin (OPG). Results: Our data shows a significant increase in plasma levels of bioactive sclerostin after KT accompanied by a significant reduction in plasma levels of Dkk-1, suggesting a promotion of the inhibition of bone formation by osteoblasts through the activation of these inhibitors of the Wnt signaling pathway. In addition, we found a significant increase in plasma levels of free sRANKL after KT accompanied by a significant reduction in plasma levels of its decoy receptor OPG, suggesting an enhanced bone resorption by osteoclasts mediated by this mechanism. Conclusions: Taken together, these results suggest that the loss of bone volume observed after KT could be explain mainly by the inhibition of bone formation mediated by sclerostin accompanied by an enhanced bone resorption mediated by sRANKL.


  • MO057TYPES OF RENAL OSTEODYSTROPHY IN A PORTUGUESE PRE-DIALYSIS COHORT

    by Ricardo Neto, Juliana Magalhães, Catarina Meng, João Frazão, Luciano Pereira, Catarina Carvalho

    INTRODUCTION AND AIMS: Renal osteodystrophy (ROD) is an early and common event in the progression of chronic kidney disease (CKD). There is relatively little knowledge about the spectrum of ROD in pre-dialysis patients. Histomorphometry is the gold standard for assessing ROD, but there is a lack of data on bone histology in pre-dialysis CKD. Studies are mostly old and inconsistent.Histomorphometric results of bone biopsies performed on a group of pre-dialysis patients are reported.

  • Cortical bone analysis in a predialysis population: a comparison with a dialysis population

    by Catarina Carvalho, J. Magalhães, R. Neto, L. Pereira, P. Branco, T. Adragão, J. M. Frazão

    This study was designed to characterize cortical bone by histomorphometry in a predialysis population, to correlate turnover, mineralization, and volume between cortical and trabecular bone, and to compare the findings with those in patients treated with maintenance dialysis. We evaluated cortical bone by histomorphometry in 16 patients with stage 3 or stage 4 chronic kidney disease and in 16 dialysis patients. Dual-energy X-ray absorptiometry (DXA) of the distal end of the forearm was performed in seven predialysis patients, and the findings correlated with histologic parameters. Predialysis patients compared with dialysis patients showed increased cortical bone thickness (p = 0.027) and decreased osteonal bone formation rate (p = 0.020) and adjusted apposition rate (p = 0.018), mainly for external cortical bone. In this predialysis population, trabecular bone volume positively correlated with external cortical porosity (r = 0.723, p = 0.003), external cortical thickness (r = 0.569, p = 0.034), and external osteonal accumulation (osteonal osteoid thickness, r = 0.530, p = 0.05; osteonal osteoid volume to bone volume ratio, r = 0.921, p < 0.001; and osteonal osteoid surface to bone surface ratio, r = 0.631, p = 0.016). These correlations were not observed in the internal cortical bone. Cortical osteonal mineralization surface negatively correlated with DXA Z and T scores and bone mineral density for the distal end of the forearm. The osteonal bone formation rate of both internal cortical bone and external cortical bone correlated with Z score (r = −0.975, p = 0.005 and r = −0.880, p = 0.021 respectively). We found no significant correlations between cortical thickness or porosity and DXA parameters for either external cortical bone or internal cortical bone. Our results suggest that a greater degree of kidney disease is associated with thinner cortices, eventually contributing to the higher fracture rate observed in the chronic kidney disease population. In predialysis patients, parathyroid hormone seems to have a modulating effect on both trabecular bone and cortical bone, particularly in external cortical bone.


  • Evolution of bone disease after kidney transplantation: A prospective histomorphometric analysis of trabecular and cortical bone

    by Catarina Carvalho, Juliana Magalhães, Luciano Pereira, Liliana Simões‐Silva, Inês Castro‐Ferreira, João Miguel Frazão

    Aim: Post‐transplant bone disease results from multiple factors, including previous bone and mineral metabolism disturbances and effects from transplant‐related medications. Bone biopsy remains the gold‐standard diagnostic tool.Methods: We aimed to prospectively evaluate trabecular and cortical bone by histomorphometry after kidney transplantation. Seven patients, willing to perform follow‐up bone biopsy, were included in the study. Dual‐X‐ray absorptiometry and trans‐iliac bone biopsy were performed within the first 2 months after renal transplantation and repeated after 2–5 years of follow‐up.Results: Follow‐up biopsy revealed a significant decrease in osteoblast surface/bone surface (0.91 ± 0.81 to 0.47 ± 0.12%, P = 0.036), osteoblasts number/bone surface (0.45 (0.23, 0.94) to 0.00/mm2, P = 0.018) and erosion surface/bone surface (3.75 ± 2.02 to 2.22 ± 1.38%, P = 0.044). A decrease in trabecular number (3.55 (1.81, 2.89) to 1.55/mm (1.24, 2.06), P = 0.018) and increase in trabecular separation (351.65 ± 135.04 to 541.79 ± 151.91 μm, P = 0.024) in follow‐up biopsy suggest loss in bone quantity. We found no significant differences in cortical analysis, except a reduction in external cortical osteonal eroded surface (5.76 (2.94, 13.97) to 3.29% (0.00, 6.67), P = 0.043). Correlations between bone histomorphometric and dual‐X‐ray absorptiometry parameters gave inconsistent results.Conclusions: The results show a reduction in bone activity, suggesting increased risk of adynamic bone and loss of bone volume. Cortical bone seems less affected by post‐transplant biological changes in the first years after kidney transplantation.


  • Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin‐free regimen

    by Catarina Carvalho, Luis Coentrão, Manuela Bustorff, Emilia Patrício, Susana Sampaio, Joana Santos, Gerardo Oliveira, Manuel Pestana

    Everolimus (EVL) and sirolimus (SRL) were introduced into immunosuppressive regimens, in an attempt to replace or reduce the dose of the nephrotoxic calcineurin inhibitors (CNI). In our institution, due to an administrative decision, conversion from SRL to EVL, was carried out, providing us the opportunity to investigate the effectiveness and safety profile of both drugs and to review the practical conversion dose between them. We retrospectively analyzed the medical records of 51 maintenance kidney transplant recipients receiving an SRL-based CNI-free regimen, who were switched to EVL. SRL dose was concentration controlled to a through level of 4-8 ng/mL. Patients were converted to a variable dose of EVL that was adjusted to achieve a trough concentration of 3-8 ng/mL. SRL mean dose at time of conversion was 2.0 ± 0.9 mg/d. Initial EVL mean dose was 1.3 ± 0.5 mg/d. Six months after conversion, mean EVL trough level was 6.2 ± 2.8 ng/mL. EVL dose at this point was 2.0 ± 0.9 mg/d, which was not statistically different from SRL dose at the time of conversion (p = 0.575), suggesting a conversion factor of 1:1. During this six month period post conversion, no significant changes were observed in serum creatinine, hematocrit level, platelet count, proteinuria or lipid levels. No patient experienced an acute rejection episode. Conversion from SRL to EVL in renal transplant recipients receiving a CNI-free immunosuppressive regimen can be performed safely with a low trough level range of EVL. We report for the first time a conversion factor between SRL and EVL.


  • Cerebral coccidioidomycosis after renal transplantation in a non-endemic area

    by C. Carvalho, I. Ferreira, S. Gaião, S. Guimarães, R. Costa, J. Santos, S. Sampaio, M. Bustorff, G. Oliveira, M. Pestana

    C. Carvalho, I. Ferreira, S. Gaião, S. Guimarães, R. Costa, J. Santos, S. Sampaio, M. Bustorff, G. Oliveira, M. Pestana. Cerebral coccidioidomycosis after renal transplantation in a non‐endemic area.Transpl Infect Dis 2010: 12: 151–154. All rights reserved Coccidioidomycosis is a fungal infection caused by Coccidioides species endemic to the desert south western United States. In healthy people, manifestations range mainly from asymptomatic to mild influenza‐like syndrome. In immunosuppressed patients, extrapulmonary dissemination is common. We report the case of a patient with a parenchymal central nervous system lesion. This presentation is considered very rare. The highest risk of infection after solid organ transplantation occurs during the first year. Risk factors include treatment of acute rejection. In the reported case, the infection was probably donor‐derived, as our patient had no history of traveling to endemic areas. Mortality is high among transplanted recipients with coccidioidomycosis, particularly those with disseminated infection.